Genix Pharmaceuticals Corporation
GENX.V
TSX
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.51% | 7.76% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.46% | 7.69% | |||
| Operating Income | 5.46% | -7.69% | |||
| Income Before Tax | -9.38% | -66.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.38% | -66.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.38% | -66.12% | |||
| EBIT | 5.46% | -7.69% | |||
| EBITDA | 5.51% | -7.76% | |||
| EPS Basic | -10.00% | -66.67% | |||
| Normalized Basic EPS | 0.00% | -50.00% | |||
| EPS Diluted | -10.00% | -66.67% | |||
| Normalized Diluted EPS | 0.00% | -50.00% | |||
| Average Basic Shares Outstanding | 2.15% | 0.00% | |||
| Average Diluted Shares Outstanding | 2.15% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||